Key Points {#FPar1}
==========

Within 24 months of starting second-line therapy at a large HIV clinical cohort in South Africa, close to half of the patients (3429/7708, 44.5%) had experienced at least one second-line antiretroviral therapy-related adverse event (AE).Rates of AEs among patients receiving second-line regimens such as TDF + FTC/3TC + LPVr are lower than that of patients receiving other regimens (3TC + ABC + LPVr/ATVr; AZT + ddI + LPVr; AZT + 3TC + LPVr/ATVr).In resource-limited settings such as South Africa, where access to third-line therapy is not guaranteed, the early detection and effective management of AEs, including low-grade AEs, could improve patient outcomes in second-line therapy.

Introduction {#Sec1}
============

Over the past 2 decades, expanded access to antiretroviral therapy (ART), in combination with more tolerable regimens, has shifted the impact of human immunodeficiency virus (HIV) infection from causing a fatal disease to a treatable chronic condition. South Africa is currently home to an estimated 7.2 million HIV-1-infected persons and has responded to the epidemic by enrolling 56% (approximately 3,831,730) of HIV-1-infected patients receiving ART, by 2017 \[[@CR1]\]. Furthermore, in 2017, approximately 38--45% of all HIV-1-infected persons receiving HIV treatment were virally suppressed \[[@CR2], [@CR3]\]. This wide gap between the number of HIV-1-infected patients and those who are suppressed when receiving ART, as well as the growing number of persons entering the HIV treatment cascade, will eventually increase the demand for second-line therapy \[[@CR1], [@CR3], [@CR4]\]. Currently, an estimated 17--25% of first-line ART patients in South Africa are expected to experience virologic failure (as defined by the World Health Organization \[WHO\]) within 5 years \[[@CR5]--[@CR8]\]. Moreover, data from the Right to Care (RTC) clinical cohort, one of the largest ART cohorts in the country, indicate that \> 60% of patients not responding to first-line ART are switched to second-line therapy \[[@CR9]--[@CR11]\]. Therefore, it is essential to continuously monitor and appropriately respond to treatment failure risks to keep the ART programme effective and sustainable.

While various studies have quantified and examined the impact of adverse drug reactions (ADRs) among patients receiving first-line therapy, very few have looked at patients receiving second-line ART. In a systematic review examining the efficacy of treatment among ART-naive HIV-infected patients in Rome (Italy), early cessation of first-line ART (within 48 weeks of treatment initiation) was estimated at 25%, with the most common reasons being by patients' decision (11%), 8% due to ADRs (8%), and 4% due to virologic failure (4%) \[[@CR12]\]. We recently demonstrated that South African patients with possible ADRs receiving second-line ART were more likely (approximately 30%) to experience treatment interruption within 2 years of second-line initiation \[[@CR13]\]. While early treatment cessation has declined over the years, the removal of CD4 count eligibility criteria for starting ART will likely increase the number of asymptomatic individuals initiated on ART. These relatively healthy patients may be less tolerant of ART-associated ADRs, which may reverse the recent gains made in retention in HIV treatment. Although access to ART has significantly improved, patients in resource-limited settings (including South Africa) still have few HIV treatment options beyond second-line ART, hence the need to closely monitor ART-related ADRs among patients receiving second-line ART \[[@CR13], [@CR14]\]. However, the growth of the South African ART programmes was not followed by an equivalent growth in adverse event (AE) monitoring systems, and routine clinical data on ART AEs offers, at best, indicators of ART-associated ADRs.

This study aimed to use routine data to estimate the rate of, and examine predictors of, second-line ART-associated AEs (as a proxy for ADRs) in the first 24 months of second-line ART among adult HIV-1-infected patients in the RTC clinical cohort in South Africa.

Methods {#Sec2}
=======

Study Design, Site and Population {#Sec3}
---------------------------------

Using prospectively collected routine clinical data, we conducted a cohort study of adult (≥ 18 years of age at second-line ART initiation) HIV-1-infected patients who initiated standard first-line ART (Table [1](#Tab1){ref-type="table"}) and subsequently permanently switched to standard second-line ART (triple combination ART, including a standard protease inhibitor \[PI\]) between 1 April 2004 and 10 January 2016 within the RTC clinical cohort in South Africa \[[@CR9], [@CR15]--[@CR20]\]. The analytic dataset included data from the date of second-line ART initiation (baseline) to 24 months post second-line ART initiation.Table 1Standard first- and second-line antiretroviral therapy regimens in South AfricaStandard first-line regimensStandard second-line regimensTDF + 3TC/EFV + EFV/NVPAZT/ABC-3TC-LPVrAZT + 3TC + EFV/NVPTDF-3TC/FTC-LPVrd4T + 3TC + EFV/NVPAZT/ABC-3TC-ATVrABC + 3TC + EFV/NVPTDF-3TC/FTC-ATVr*TDF* tenofovir, *3TC* lamivudine, *EFV* efavirenz, *NVP* nevirapine, *AZT* zidovudine, *d4T* stavudine, *ABC* abacavir, *LPVr* lopinavir/ritonavir, *FTC* emtricitabine, *ATVr* atazanavir/ritonavir

The RTC clinical cohort consists of 10 clinics (three non-governmental organisation \[NGO\]-run clinics, four public Community Health Centres (CHCs) and three ART clinics embedded in public hospitals) located in the Gauteng and Mpumalanga provinces in South Africa \[[@CR9]\]. The clinics were established or expanded as part of the public sector scale-up of ART in the country and receive technical support from RTC, an NGO that is funded by the United States Agency for International Development (USAID). HIV care and treatment within the RTC clinical cohort follows South African National ART guidelines \[[@CR15]--[@CR20]\]. During the study period, CD4 threshold for ART eligibility criteria was revised from ≤ 200 cells/µL in the 2004 guidelines to ≤ 350 cells/µL in the 2013 guideline update, and ≤ 500 cells/µL in 2015. CD4 thresholds were removed from the 2016 HIV treatment policy \[[@CR15]--[@CR20]\]. Moreover, patients not responding to first-line ART (two consecutive viral loads ≥ 1000 copies/mL within a 3-month period, with intensified adherence counselling administered between viral loads) are eligible to switch to second-line therapy \[[@CR19]\]. Additionally, in the absence of virologic failure, the decision to switch a patient to second-line therapy may also be made based on diagnosed AEs/resistance to first-line drugs.

Clinical data, including laboratory data from the National Health Laboratory Services (NHLS), from the ART clinics were captured on site and stored in an electronic patient management system, TherapyEdge-HIV™ \[[@CR9]\].

Analytic Variables {#Sec4}
------------------

### Adverse Events (AEs) in the Initial 24 Months of Second-Line Antiretroviral Therapy (ART) {#Sec5}

In the absence of reliable pharmacovigilance ADR data, we use second-line ART-related AEs as proxy measures. Therefore, the primary outcome was the first occurrence of any one of the following ART-related conditions during medical visits, up to 24 months after second-line ART initiation: dyslipidaemia, dermatitis/skin conditions neuropathy, diarrhoea/nausea/vomiting, gynaecomastia/breast conditions, hepatitis, lactic acidosis, decreased kidney function, anaemia, depression, and sleep disorders/insomnia. These conditions have previously been identified as possible drug reactions to both first- and second-line ARVs \[[@CR21]\].

These conditions were ascertained by abstraction from clinical visit notes. However, in addition to clinical notes, anaemia episodes were also identified using haemoglobin (Hb) measurements defined as Hb \< 13.0 g/dL in men and \< 12.0 g/dL in women. Similarly, episodes of renal insufficiencies while receiving second-line ART were also identified using estimated glomerular filtration rate (eGFR) measures. Renal problems were defined as eGFR ≤ 59 mL/min/1.73 m^2^ for both males and females.

AEs were also identified up to 6 months before the switch to second-line ART to allow adjustments for unresolved AEs that occurred while receiving first-line ART. AEs occurring while receiving second-line ART were distinguished from those occurring while receiving first-line therapy by the respective start dates of each AE. In addition to the first occurrence of an AE, a measure of the frequency of AEs up to 24 months after the switch to second-line ART was determined.

### Baseline Explanatory Variables {#Sec6}

We defined baseline as the time of initiating second-line ART, and indicators were considered baseline if they were taken up to 3 months before the initiation of second-line ART. Baseline data included (1) demographic variables; (2) clinical and laboratory variables (e.g. WHO stage, body mass index \[BMI\], CD4 count and viral load); and (3) treatment variables (e.g. ART regimen, and treatment start and stop date). WHO staging information is generally interpreted as asymptomatic, mildly symptomatic, moderately symptomatic, and severely symptomatic. BMI (measured in kg/m^2^) was categorised as being underweight (BMI \< 18.5), normal (18.5 ≤ BMI \< 25), overweight (25 ≤ BMI \< 30), and obese (BMI ≥ 30). Additionally, we included a variable summarising the CD4 response when receiving first-line ART, defined as the change in CD4 count from first-line ART initiation to the date of switching to second-line ART.

Follow-Up Time {#Sec7}
--------------

Person-time accrued from the date of second-line ART initiation until the outcome of interest, completion of 24 months of second-line ART, or the last date seen at the clinic during the first year of second-line ART (for those who died, were lost to follow-up \[LTFU\], or transferred out).

Statistical Analysis {#Sec8}
--------------------

Data analysis was conducted using STATA version 14 (StataCorp LLC, College Station, TX, USA). Baseline demographic and clinical characteristics were presented using medians and interquartile ranges (IQRs) for continuous variables, while categorical variables were described using percentages. Kaplan--Meier survival analysis was used to determine the incidence of AEs in the first 24 months of second-line ART. Predictors of experiencing an AE (first reported AE within 24 months of second-line initiation) were modelled using complete case analysis with the use of a Cox proportional hazards model. Models were adjusted for baseline demographic and clinical characteristics. Additionally, we looked at the frequency of AEs by the initial second-line ART regimens.

Variables with a *p* value \< 0.05 in crude analyses were entered in the multivariate model. Schoenfeld residuals were used to test the assumption of proportional hazards. Interaction terms with time-varying covariates were created for variables that violated the proportional hazards assumption. Variables were excluded from the multivariate model when the inclusion of the interaction term did not resolve the proportional hazards assumption violation, except for the initiating second-line regimen, in which case the model was stratified.

Results {#Sec9}
=======

Cohort Description and Baseline Characteristics {#Sec10}
-----------------------------------------------

Table [2](#Tab2){ref-type="table"} presents the demographic and clinical characteristics of the study cohort at second-line ART initiation (*N* = 7708). Nearly two-thirds of the cohort were female (65.0%), and the median age at second-line initiation was 37.4 years (IQR 32.3--43.9). The median CD4 cell count at second-line ART initiation was 212 cells/µL (IQR 101--344), with 47.2% of patients switching to second-line therapy at a CD4 cell count of \< 200 cells/µL. The majority of patients were switched to second-line ART with viral loads ≥ 1000 copies/mL (82.9%). Nearly half of all patients had a normal BMI (47.8%), while close to two-thirds of patients were at WHO stage I (62.8%) at the time of switching to second-line ART.Table 2Demographic and clinical characteristics of patients initiating second-line antiretroviral therapy from 1 April 2004 to 10 January 2016VariablesTotal \[*N* = 7708\]Sex at second-line initiation Female5010 (65.0) Male2698 (35.0)Age at second-line initiation, years Median (IQR)37.4 (32.3--43.9) 18--291220 (15.8) 30--393489 (45.3) ≥ 402999 (38.9)CD4 cell count at second-line initiation, cells/mm^3^ Median (IQR)212 (101--344) 0--1991436 (47.2) 200--349864 (28.4) ≥ 350742 (24.4)Viral load at second-line initiation, copies/mL Median (IQR)11,841 (2100--60,784) \< 1000941 (17.0) 1000--99991686 (30.5) ≥ 10,0002896 (52.4)BMI at second-line initiation Underweight440 (7.8) Normal2681 (47.8) Overweight1530 (27.3) Obese959 (17.1)WHO stage at second-line initiation I2580 (62.8) II582 (14.2) III/IV944 (23.0)Time on first-line ART before the switch, months Median (IQR)25.5 (13.8--44.8) 0--121564 (20.3) 12--242086 (27.1) ≥ 244058 (52.7)Regimen at second-line initiation 3TC + ABC + LPVr238 (3.1) AZT + 3TC + LPVr/ATVr2686 (34.9) AZT + ddI + LPVr1501 (19.5) TDF +  FTC/3TC + LPVr3283 (42.6)Year of second-line initiation 2004--20091895 (24.6) 2010--20123618 (46.9) 2013--20162195 (28.5)Non-ARV comedication at second-line initiation No4752 (61.7) Yes2956 (38.4)\*Time (days) to first AE in the first 24 months of second-line ART Median (IQR)84 (28--237) 0--901810 (52.8) 91--180547 (16.0) ≥ 1811072 (31.3)Time (days) to first AE in the first 24 months of second-line ART by initial second-line regimen \[medium (IQR)\]\* ABC + 3TC + LPVr/ATVr57 (5--155) AZT + 3TC + LPVr/ATVr56 (26--181) AZT + ddI + LPVr85 (28--224) TDF +  FTC/3TC + LPVr134 (28--308)Data are expressed as *n* (%) unless otherwise specified*IQR* interquartile range, *BMI* body mass index, *WHO* World Health Organization, *ART* antiretroviral therapy, *ARV* antiretroviral, *3TC* lamivudine, *ABC* abacavir, *LPVr* lopinavir/ritonavir, *ATVr* atazanavir/ritonavir, *AZT* zidovudine, *ddI* didanosine, *TDF* tenofovir, *FTC* emtricitabine, *AE* adverse event

At the time of second-line ART initiation, 52.7% of patients had been receiving first-line ART for 2 or more years. Overall, 42.6% of patients initiated second-line ART on a regimen of tenofovir (TDF) + emtricitabine (FTC)/lamivudine (3TC) + ritonavir-boosted lopinavir (LPVr), 34.9% were prescribed zidovudine (AZT) + 3TC + LPVr/ritonavir-boosted atazanavir (ATVr), and 19.5% were prescribed AZT + didanosine (ddI) + LPVr. Only 3.1% were switched to 3TC + abacavir (ABC) + LPVr.

AEs in the First 24 Months of Second-Line ART {#Sec11}
---------------------------------------------

Overall, 3429 (44.5%) patients experienced an AE in the first 24 months of second-line treatment (Table [3](#Tab3){ref-type="table"}). The overall rate of AEs while receiving second-line ART was 36.7/100 person-years (PYs; 95% confidence interval \[CI\] 35.3--38.1). This was highest among patients receiving a regimen including ABC (52.7/100 PYs, 95% CI 42.9--64.8) or ddI (51.2/100 PYs, 95% CI 47.5--55.2), while patients switched to a TDF- (26.5/100 PYs, 95% CI 24.9--28.3) or AZT-based second-line regimen had the lowest AE rates (42.8/100 PYs, 95% CI 40.2--45.5). Table [3](#Tab3){ref-type="table"} presents the first AE experienced by the initial second-line ART regimen, up to 24 months of second-line ART.Table 3Details of AEs, drug substitutions and treatment interruptions among patients with incident AEs up to 24 months of second-line initiationInitial second-line ART regimenTotal3TC + ABC + LPVr/ATVrAZT + 3TC + LPVr/ATVrAZT + ddI + LPVrTDF + FTC/3TC +  LPVr*n* (col %)*n* (col %)*n* (col %)*n* (col %)*n* (col %)\[*N* = 117\]\[*N* = 1298\]\[*N* = 822\]\[*N* = 1192\]\[*N* = 3429\]First AE in the observation period Anaemia80 (68.4)1015 (78.2)524 (63.6)711 (59.7)2330 (68.0) Decreased kidney function28 (23.9)77 (5.9)8 (1.0)151 (12.7)264 (7.7) Dyslipidaemia2 (1.7)68 (5.2)60 (7.3)115 (9.7)245 (7.1) Gastrointestinal conditions2 (1.7)52 (4.0)83 (10.1)82 (6.9)219 (6.4) Neuropathy2 (1.7)28 (2.2)44 (5.4)52 (4.4)126 (3.7) Skin conditions3 (2.6)29 (2.2)49 (6.0)40 (3.4)121 (3.5) Others--29 (2.2)54 (6.6)41 (3.4)124 (3.6)Frequency of AE episodes in the initial 24 months of second-line ART One39 (33.3)594 (45.8)342 (41.6)681 (57.1)1656 (48.3) Two20 (17.1)335 (25.8)209 (25.4)264 (22.2)828 (24.2) Three or more58 (49.6)369 (28.4)271 (33.0)247 (20.7)945 (27.6)Drug substitutions on second-line ART (24 months) None177 (74.4)2097 (78.1)885 (59.0)2608 (79.4)5767 (74.8) One38 (16.0)345 (12.8)446 (29.7)471 (14.4)1300 (16.9) Two12 (5.0)171 (6.4)134 (8.9)154 (4.7)471 (6.1) Three or more11 (4.6)70 (2.6)36 (2.4)50 (1.5)167 (2.2)Treatment interruptions on second-line ART (24 months) None216 (90.8)2491 (92.7)1273 (84.8)3019 (92.0)6999 (90.8) One19 (8.0)180 (6.7)205 (13.7)243 (7.4)647 (8.4) Two2 (0.8)13 (0.5)22 (1.5)17 (0.5)54 (0.7) Three or more1 (0.4)2 (0.1)1 (0.1)4 (0.1)8 (0.1)*AEs* adverse events, *ART* antiretroviral therapy, *3TC* lamivudine, *ABC* abacavir, *LPVr* lopinavir/ritonavir, *ATVr* atazanavir/ritonavir, *AZT* zidovudine, *ddl* didanosine, *TDF* tenofovir, *FTC* emtricitabine

Anaemia was the most common first AE experienced, with 2389 first AE cases (31.0% prevalence and 68.0% of all AEs); 78.5% of these anaemia episodes were mild (24.0% overall), 16.9% were moderate (5% overall), and 4.6% were severe (1.0% overall) (Fig. [1](#Fig1){ref-type="fig"}). Nearly half (43.6%) of all first anaemia cases were among patients receiving AZT + 3TC + LPVr/ATVr, while the next most common AE was decreased kidney function (264 cases, or 3% overall), among which 90.9% were mild, 6.3% were moderate and 2.8% were severe cases. Kidney problems were less likely among patients receiving TDF + FTC/3TC + LPVr (5.0% overall) compared with patients receiving ABC + 3TC + LPVr/ATVr (12.0%). After anaemia (35.0% overall), patients receiving AZT + ddI + LPVr also experienced gastrointestinal conditions (6.0%) and dyslipidaemia (4.0%).Fig. 1Proportion of incident adverse events in initial 24 months of second-line ART among HIV-1 infected patients in South Africa

Predictors of AEs in the First 24 Months of Second-Line ART {#Sec12}
-----------------------------------------------------------

Table [4](#Tab4){ref-type="table"} presents the crude (hazard ratio \[HR\]) and adjusted HR (aHR) estimates of experiencing an AE in the first 24 months of second-line ART. In adjusted analyses, when compared with patients initiating second-line ART of TDF + FTC/3TC + LPVr, patients receiving AZT + ddI + LPVr (aHR 1.5, 95% CI 1.2--1.9) and AZT + 3TC + LPVr/ATVr (aHR 1.3, 95% CI 1.1--1.1) were more likely to experience AEs while receiving second-line ART.Table 4Unadjusted and adjusted estimates of the relationship between demographic and clinical characteristics at second-line ART initiation with AEs by 24 months after second-line ART initiationVariableCox hazard regression modelling with total sampleCox regression stratified by first second-line ART regimenLogistic regression modelling risk of having two or more AEs in the first 24 months (patients with one or more AEs)*n* (row%)Rate/100PY (95% CI)Crude HRAdjusted HRAdjusted HR\
TDF + FTC/3TC + LPVrAdjusted HR\
AZT +  + 3TC + LPVr/ATVrAdjusted HR\
AZT + ddI + LPVrCrude odds ratioAdjusted\
odds ratioADRs 6 months prior to second-line ART initiation No1989 (36.9)27.3 (26.0--28.7)1111111 Yes1440 (62.1)71.2 (67.2--75.5)2.4 (2.2--2.6)2.3 (1.9--2.8)2.3 (1.7--3.2)2.7 (1. 9--3.9)2.3 (1.7--3.0)2.5 (2.1--2.8)2.3 (1.8--2.9)Sex at second-line initiation Female2372 (47.4)41.3 (39.4--43.2)1111111 Male1057 (39.2)29.4 (27.5--31.4)0.8 (0.7--0.8)0.6 (0.5--0.7)0.4 (0.3--0.7)0.7 (0.5--1.1)0.5 (0.4--0.7)0.8 (0.7--0.9)0.7 (0.5--0.9)Age at second-line initiation, years 18--30522 (42.8)37.9 (34.5--41.7)1111111 30--401517 (43.5)35.2 (33.3--37.3)1.0 (0.9--1.1)1.3 (1.0--1.6)1.0 (0.7--1.6)1.3 (0.7--2.2)1.4 (1.0--2.1)1.0 (0.8--1.2)1.1 (0.8--1.6) ≥401390 (46.4)37.9 (35.7--40.2)1.0 (0.9--1.1)1.4 (1.0--1.8)1.1 (0.7--1.8)1.2 (0.7--2.1)1.5 (1.0--2.2)1.0 (0.9--1.3)1.1 (0.7--1.6)CD4 cell count at second-line initiation, cells/mm^3^ 0--199768 (53.5)55.7 (51.6--60.2)1.8 (1.5--2.1)1.4 (1.0--1.8)0.7 (0.4--1.3)1.8 (1.0--3.2)1.8 (1.1--3.0)2.1 (1.6--2.8)1.6 (1.0--2.4) 200--349403 (46.6)38.8 (34.9--43.2)1.3 (1.1--1.5)1.2 (0.9--1.5)0.8 (0.5--1.1)1.1 (0.7--1.8)1.6 (1.0--2.6)1.7 (1.3--2.3)1.6 (1.1--2.4) ≥ 350311 (41.9)29.5 (26.0--33.5)1111111CD4 cell count change between first- and second-line ART initiation, cells/mm^3^ No change (± 50)395 (52.0)54.0 (48.5--60.1)1111111 Increase (50--100)157 (50.8)48.6 (41.0--57.5)0.9 (0.7--1.1)1.0 (0.7--1.3)1.6 (1.0--2.7)1.5 (0.8--2.7)0.6 (0.4--0.9)1.0 (0.7--1.4)1.1 (0.8--1.7) Increase (≥ 100)519 (46.5)36.5 (33.2--40.2)0.7 (0.6--0.8)1.0 (0.8--1.2)0.8 (0.5--1.2)1.5 (0.8--2.6)0.9 (0.6--1.3)0.7 (0.5--0.9)0.9 (0.6--1.4) Decrease (≥ − 50)90 (54.2)64.9 (51.9--81.1)1.2 (0.9--1.5)1.1 (0.8--1.7)2.5 (1.3--5.0)1.8 (0.9--3.9)0.6 (0.3--1.2)1.4 (0.9--2.2)1.5 (0.9--2.5)BMI at second-line initiation, kg/m^2^ Underweight257 (58.4)62.1 (53.9--71.6)1.4 (1.2--1.7)1.1 (0.8--1.5)0.9 (0.5--1.6)1.4 (0.8--2.6)1.2 (0.7--2.1)1.2 (0.9--1.6)-- Normal1265 (47.2)41.1 (38.7--43.7)111111-- Overweight651 (42.6)33.9 (31.1--36.9)0.8 (0.8--0.9)0.8 (0.6--1.0)0.7 (0.4--1.0)0.9 (0.6--1.3)0.7 (0.5--1.0)1.0 (0.8--1.2)-- Obese408 (42.5)33.3 (30.0--37.1)0.8 (0.7--0.9)0.8 (0.6--1.0)0.7 (0.5--1.2)0.6 (0.3--1.0)0.9 (0.6--1.3)0.9 (0.7--1.1)--WHO stage at second-line initiation I/II1455 (46.0)37.2 (35.1--39.4)111111-- III/IV456 (48.3)42.4 (38.3--47.0)1.1 (1.0--1.3)0.9 (0.7--1.2)1.1 (0.7--1.6)0.9 (0.6--1.4)1.1 (0.9--1.3)--Regimen at second-line initiation 3TC + ABC + LPVr/ATVr117 (49.2)52.7 (42.9--64.8)1.8 (1.5--2.3)1.0 (0.5--1.9)------2.7 (1.8--4.0)1.4 (0.5--3.9) AZT + 3TC + LPVr/ATVr1298 (48.3)42.8 (40.2--45.5)1.6 (1.4--1.7)1.3 (1.1--1.7)------1.6 (1.4--1.9)1.7 (1.2--2.3) AZT + ddI + LPVr822 (54.8)51.2 (47.5--55.2)1.9 (1.7--2.1)1.5 (1.2--1.9)------1.9 (1.6--2.2)2.0 (1.4--2.8) TDF +  FTC/3TC + LPVr1192 (36.3)26.5 (24.9--28.3)11------11First-line regimen prior to switch ABC + 3TC + EFV/NVP34 (61.8)68.5 (46.6--100.6)1.6 (1.1--2.3)3.4 (1.1--11.1)------2.5 (1.2--5.5)10.8 (1.2--94.0) TDF + 3TC/FTC + EFV/NVP1358 (45.1)40.8 (38.5--43.2)11------11 AZT + 3TC + EFV/NVP453 (41.6)31.2 (28.2--34.6)0.8 (0.7--0.9)0.9 (0.7--1.2)------0.8 (0.6--1.0)1.0 (0.7--1.5) d4T + 3TC + EFV/NVP1584 (44.6)34.9 (33.0--36.9)0.9 (0.8--1.0)1.0 (0.8--1.3)------1.0 (0.9--1.2)1.1 (0.8--1.5)Non-ARV comedication at second-line initiation No2009 (42.3%)33.6 (32.0--35.3)111111-- Yes1420 (48.0%)41.8 (39.5--44.3)1.2 (1.1--1.3)1.0 (0.8--1.2)1.4 (1.0--2.0)0.9 (0.6--1.3)0.9 (0.7--1.2)1.1 (1.0--1.3)--Global test before including interaction with time (0.00); cd4 cell count change (0.05); regimen at second-line initiation (0.00); first-line regimen prior to switch (0.01)Global test after including interaction with time (0.25); cd4 cell count change (0.44); regimen at second-line initiation (0.03); first-line regimen prior to switch (0.05)*ART* antiretroviral therapy, *ADRs* adverse drug reactions, *AEs* adverse events, *HR* hazard ratio, *PYs* person-years, *CI* confidence interval, *BMI* body mass index, *WHO* World Health Organization, *3TC* lamivudine, *ABC* abacavir, *LPVr* lopinavir/ritonavir, *ATVr* atazanavir/ritonavir, *AZT* zidovudine, *ddl* didanosine, *TDF* tenofovir, *FTC* emtricitabine, *EFV* efavirenz, *NVP* nevirapine, *TDF* tenofovir, *FTC* emtricitabine, *d4T* stavudine, *ARV* antiretroviral

In the adjusted model including the total cohort, patients who had experienced an AE in the last 6 months of first-line ART were twice more likely to experience an AE in the first 24 months of second-line ART (aHR 2.3, 95% CI 1.9--2.8). Male patients had a 43% reduced risk compared with females (aHR 0.6, 95% CI 0.5--0.7), and patients who switched to second-line ART at 40 years of age or older (HR1.4, 95% CI 1.0--1.8) were more likely to experience AEs compared with those who were younger (18--30 years) at the switch.

Patients with a lower CD4 cell count at baseline were 38.0% more likely to experience AEs (0--199 vs. ≥ 350 cells/µL: aHR 1.4, 95% CI 1.1--1.8). Patients who were underweight at second-line ART initiation had a higher risk of AEs (underweight vs. normal-weight patients: aHR 1.4, 95% CI 1.2--1.7), whereas obese and overweight patients had a reduced likelihood of AEs (overweight vs. normal BMI: aHR 0.8, 95% CI 0.6--1.0; and obese vs. normal BMI: aHR 0.8, 95% CI 0.6--1.0).

In stratified models, similar results were observed for having a history of AEs before switching to second-line ART, sex, age (in patients receiving a ddI-based regimen), WHO stage, baseline CD4 count (in patients receiving a ddI-based regimen) and BMI. Among patients who were initially switched to TDF + FTC/3TC + LPVr, a CD4 decline after first-line ART initiation was predictive of AEs while receiving second-line ART (CD4 decrease ≥ 50 cells/µL vs. no CD4 change: aHR 2.5, 95% CI 1.3--5.0).

Predictors of Experiencing Two or More AEs Among Patients Who Had Incident AEs in the First 24 Months of Second-Line ART {#Sec13}
------------------------------------------------------------------------------------------------------------------------

In logistic regression analyses, predictors of having two or more AEs among patients who had incident AEs (Table [4](#Tab4){ref-type="table"}) were having a history of AEs while receiving first-line ART (adjusted odds ratio \[aOR\] 2.3, 95% CI 1.8--2.9), having a baseline CD4 count \< 199 cells/µL compared with those with CD4 ≥ 350 cells/µL (aOR 1.6, 95% CI 1.0--2.4), starting second-line ART with AZT + 3TC + LPVr/ATV (aOR 1.7, 95% CI 1.2--2.3) or AZT + ddI + LPVr (aOR 2.0, 95% CI 1.4--2.8) compared with those who started on TDF + FTC/3TC + LPVr. Additionally, although imprecise, the risk of multiple AE episodes was higher among patients who had switched from ABC + 3TC + efavirenz/nevirapine (EFV/NVP) \[aOR 10.8, 95% CI 1.2--94.0\] compared with patients who switched from TDF + 3TC/FTC + EFV/NVP. Compared with women, male patients were less likely to have had multiple AEs in the first 2 years of second-line ART (aOR 0.7, 95% CI 0.5--0.9).

Discussion {#Sec14}
==========

We aimed to determine the rates and examine clinical predictors of developing an ART-related AE in the first 24 months of second-line ART among HIV-1-infected adult patients within the RTC clinical cohort. Overall, 44.5% of patients experienced an AE in the 24 months of observation, across second-line ART regimens. This proportion is higher than the 19% observed in a Malawi cohort (12 months follow-up) \[[@CR22]\] and 22.3% from a 2011 cross-sectional study (including children) in Uganda \[[@CR23]\]. The variations of AE rates for patients receiving second-line ART highlight the inconsistent AE reporting practices and follow-up times across settings and studies \[[@CR24]\].

Similar to other sub-Saharan African populations, we found that the rates of AEs were higher among patients receiving a second-line regimen that included AZT and ddI compared with a TDF-based regimen \[[@CR25], [@CR26]\]. The first AE was mainly anaemia, more so among patients who started second-line ART with an AZT-containing regimen. Despite the differing study methods, a cross-sectional study among patients receiving second-line ART in Malawi found similar anaemia levels, i.e. 33.2 versus 31.0% in our study \[[@CR27]\].

The second most common first AEs were kidney problems, affecting 3% of the sample. While kidney problems were expected to occur mainly among patients receiving TDF, they were more frequent among patients who were switched to an ABC-based second-line regimen \[[@CR21], [@CR28]\]. This difference in the occurrence of kidney problems among patients switched to ABC for second-line ART possibly stems from TDF contraindications or pre-existing kidney problems at the time of the switch \[[@CR29]\]. Patients who started second-line ART on an ABC-based regimen were also at considerably higher risk of frequent AEs in the first 2 years of second-line ART. Furthermore, patients who experienced AEs in the last 6 months of first-line ART were more susceptible to multiple AEs after the switch to second-line ART. Additional predictors of AEs among patients receiving second-line ART include low baseline BMI and CD4 count. The relationship between CD4 cell count and the development of AEs is unclear in recent literature, with both higher and lower CD4 cell counts having been associated with incident AEs \[[@CR30], [@CR31]\]. However, the results suggest that patients with poor health who switch to second-line ART may struggle to clear pre-existing conditions, are less able to cope with the challenge with new drugs, and require closer monitoring.

Demographic factors associated with an increased risk of AEs while receiving second-line ART were older age at second-line ART initiation (≥ 40 vs. 18--30 years) and being female. Similar to our findings, a gender difference in ART discontinuation and AE pattern has been previously observed \[[@CR32]\], with women being more likely to develop peripheral neuropathy, particularly at low Hb levels \[[@CR33]--[@CR35]\].

Limitations {#Sec15}
===========

The interpretation of these results is limited to the context from which participants were drawn. The RTC cohort consisted of patients from health facilities in Gauteng and Mpumalanga province and may not be representative of patients across South Africa. Due to the lack of formal AE reporting systems in South Africa, AE rates may be underestimated \[[@CR36]--[@CR38]\], and more systematic and structured pharmacovigilance systems are needed to improve the accuracy of reported AEs. While rates of AEs were lower among patients receiving a TDF-based regimen, 36.3% over 2 years is not negligible. Further studies with more extended follow-up periods are needed to assess the longer-term implication of AEs and the potential fluidity in predictors of such events.

Conclusions {#Sec16}
===========

TDF in second-line ART is least associated with incident and frequent AEs in the first 24 months of second-line ART. However, patients with poor health indicators at switch, those with a history of AEs while receiving first-line ART, and those with TDF contraindications are at a considerably higher risk of incident AEs when receiving second-line ART, and need closer monitoring and support in order to thrive. Furthermore, the size of the ART programme in South Africa, coupled with high rates of comorbidities, such as tuberculosis, warrants active pharmacovigilance to obtain data on actual ADRs to better monitor the second-line ART programme.
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